Hepatorenal Syndrome Treatment Market Size Projected To Increase From $16.09 Billion To $21.12 Billion During The Forecast Period
Enhanced with market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports deliver more actionable and strategically valuable research.
Hepatorenal Syndrome Treatment Market Size, Value And Growth Trends Through 2030
The market for hepatorenal syndrome treatments has experienced robust expansion over the past several years. It is projected to rise from $15.17 billion in 2025 to $16.1 billion in 2026, reflecting a compound annual growth rate of 6.1%. Historically, this growth was driven by factors such as insufficient awareness of hepatorenal syndrome, an absence of uniform treatment guidelines, elevated death rates linked to liver failure, reliance on traditional dialysis techniques, and constrained availability of cutting-edge therapies.
Over the coming years, the market for hepatorenal syndrome treatment is projected to experience robust expansion, with its value anticipated to reach $21.12 billion by 2030, reflecting a compound annual growth rate (CAGR) of 7.0%. This upward trajectory during the forecast period can be linked to progress in targeted therapies, the growing use of precision medicine, enhanced healthcare infrastructure, the incorporation of artificial intelligence and digital tools for patient monitoring, and heightened investment in the development of new drugs. Key trends shaping this period involve a rising incidence of chronic liver conditions, improvements in renal replacement therapies, customized treatment strategies for hepatorenal syndrome, expansion of hospital and clinical facilities, and a stronger emphasis on early detection and ongoing observation.
Download A Free Sample Report For Comprehensive Market Insights:
Hepatorenal Syndrome Treatment Market Industry Drivers: What Is Driving Revenue Growth?
The anticipated expansion of the hepatorenal syndrome treatment market is being driven by the growing prevalence of fast-track and novel drug designations. These designations represent regulatory mechanisms that accelerate the development, review, and approval of drugs targeting serious conditions with unmet medical needs, with the goal of delivering innovative treatments to patients more efficiently. Their increasing adoption aims to speed up the creation of therapies for hepatorenal syndrome by responding to the pressing demand for effective options, potentially enhancing patient prognoses and addressing gaps in current care. As an example, in January 2024, the Center for Drug Evaluation and Research (CDER), a U.S. branch of the Food and Drug Administration (FDA), released the New Drug Therapy Approvals 2023 report, which revealed that 55 novel drugs were approved in 2023, 20 of which (36%) were classified as first-in-class, compared to 37 novel approvals in 2022. Consequently, the rise in fast-track and novel drug designations is fueling growth in the hepatorenal syndrome treatment market.
Hepatorenal Syndrome Treatment Market Driver: Rising Healthcare Spending Fueling Growth In The Hepatorenal Syndrome Treatment Market
Growth in the hepatorenal syndrome treatment market is expected to be propelled by an increase in healthcare spending. Healthcare spending encompasses the total expenditure across all economic sectors on hospitals, home health services, prescription drugs, nursing homes, and personal healthcare. With higher healthcare spending, more resources may be allocated to research and development for more effective and innovative HRS treatments. This increased financial commitment may also improve access to screening tools and early detection methods for HRS, facilitating earlier intervention and better outcomes. For example, according to the Office for National Statistics (ONS), a UK-based independent statistical body, in April 2025, total healthcare expenditure rose by 6.5% in nominal terms and 2.4% in real terms between 2023 and 2024, while healthcare’s GDP share remained consistent at 11.1% in 2024, matching the prior year. Thus, the surge in healthcare spending is advancing the hepatorenal syndrome treatment market.
Hepatorenal Syndrome Treatment Market Segment Performance And Strategic Opportunities
The hepatorenal syndrome treatment market covered in this report is segmented –
1) By Type: Type 1 Hepatorenal Syndrome, Type 2 Hepatorenal Syndrome
2) By Treatment: Therapeutics, Surgical Treatment
3) By End-User: Hospitals And Clinics, Ambulatory Surgical Centers, Academic And Research Institutes, Other End-Users
Subsegments:
1) By Type 1 Hepatorenal Syndrome: Intravenous Albumin, Vasopressors, Dialysis, Liver Transplantation
2) By Type 2 Hepatorenal Syndrome: Albumin Infusion, Midodrine, Octreotide, Liver Transplantation
Hepatorenal Syndrome Treatment Market Growth Trends: What Is Influencing The Future Outlook?
Key players in the hepatorenal syndrome treatment market are concentrating on creating cutting-edge innovations, including vasoconstrictive renal-support therapies, aimed at enhancing kidney function and improving clinical results for patients experiencing rapid deterioration due to advanced liver disease. This type of therapy involves a pharmacological approach that boosts renal perfusion and aids kidney recovery by selectively narrowing splanchnic blood vessels and stabilizing circulatory function. As an example, in June 2024, Mallinckrodt plc, a specialty pharmaceutical company based in Ireland, unveiled fresh clinical data for TERLIVAZ, a terlipressin injection approved for hepatorenal syndrome accompanied by a swift decline in kidney function. The results showed positive outcomes across various patient groups, such as higher rates of kidney dysfunction reversal and a decreased need for renal replacement therapy. Additionally, the data highlighted the treatment’s importance in managing a life-threatening complication of advanced liver disease and its capacity to facilitate earlier detection and more effective clinical care.
Hepatorenal Syndrome Treatment Market Key Players: Which Companies Shape Industry Competition?
Major companies operating in the hepatorenal syndrome treatment market are BioVie Inc., Cumberland Pharmaceuticals Inc., Mallinckrodt Pharmaceuticals, Orphan Therapeutics LLC, Baxter International Inc., Novartis AG, Eli Lilly and Company, Johnson & Johnson, Boehringer Ingelheim GmbH, Bayer AG, Gilead Sciences Inc., Pfizer Inc., AstraZeneca PLC, AbbVie Inc., Amgen Inc., F Hoffmann-La Roche Ltd, Takeda Pharmaceutical Company Limited, Daiichi Sankyo Company Limited, Teva Pharmaceutical Industries Ltd., Otsuka Pharmaceutical Co Ltd, Astellas Pharma Inc., Kyowa Kirin Co Ltd
Access The Complete Hepatorenal Syndrome Treatment Market Report:
Hepatorenal Syndrome Treatment Market Leading Geography: Which Region Generates The Most Revenue?
North America was the largest region in the hepatorenal syndrome treatment market in 2025. Asia-Pacific is expected to be the fastest-growing region in the global hepatorenal syndrome treatment market during the forecast period. The regions covered in the hepatorenal syndrome treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
